Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma (VTEPX)

This study has been completed.
Sponsor:
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
Ernest Moore, Denver Health and Hospital Authority
ClinicalTrials.gov Identifier:
NCT01050153
First received: January 13, 2010
Last updated: November 28, 2014
Last verified: November 2014
History of Changes
Results First Received: August 14, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Condition: Venous Thromboembolism
Interventions: Drug: Dalteparin sodium
Drug: Dalteparin sodium/aspirin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
50 consecutive eligible patients admitted to the Surgical Intensive Care Unit following trauma between March 2010 and December 2011 were enrolled in the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Control (Standard of Care)

Dalteparin sodium 5000IU subcutaneously daily

Dalteparin sodium : Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
TEG-guided Thromboprophylaxis

Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm

Dalteparin sodium/aspirin : Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily)po.

Participant Flow:   Overall Study
    Control (Standard of Care)     TEG-guided Thromboprophylaxis  
STARTED     25     25  
COMPLETED     25     25  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Control (Standard of Care)

Dalteparin sodium 5000IU subcutaneously daily

Dalteparin sodium : Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
TEG-guided Thromboprophylaxis

Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm

Dalteparin sodium/aspirin : Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily)po.
Total Total of all reporting groups

Baseline Measures
    Control (Standard of Care)     TEG-guided Thromboprophylaxis     Total  
Number of Participants  
[units: participants]
 		  25     25     50  
Age  
[units: participants]
 		     
<=18 years     0     0     0  
Between 18 and 65 years     25     25     50  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation 		  40.04  ± 12.18     38.44  ± 14.34     39.24  ± 13.19  
Gender  
[units: participants]
 		     
Female     6     8     14  
Male     19     17     36  
Region of Enrollment  
[units: participants]
 		     
United States     25     25     50  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Hypercoagulability   [ Time Frame: Study day five. ]
  Show Outcome Measure 1

2.  Primary:   Incidence of VTE   [ Time Frame: Day 28 or discharge, whichever comes first. ]
  Show Outcome Measure 2

3.  Secondary:   TEG Parameters   [ Time Frame: Study day five. ]
  Show Outcome Measure 3

4.  Secondary:   International Normalized Ratio (INR)   [ Time Frame: Study day five. ]
  Show Outcome Measure 4

5.  Secondary:   Platelet Count   [ Time Frame: Study day five. ]
  Show Outcome Measure 5

6.  Secondary:   TEG Parameters   [ Time Frame: Study day five. ]
  Show Outcome Measure 6

7.  Secondary:   Conventional Coagulation Testing Parameters   [ Time Frame: Study day five. ]
  Show Outcome Measure 7

8.  Secondary:   Conventional Coagulation Testing Parameters   [ Time Frame: Study day five. ]
  Show Outcome Measure 8

9.  Secondary:   Conventional Coagulation Testing Parameters   [ Time Frame: Study day five. ]
  Show Outcome Measure 9

10.  Secondary:   Conventional Coagulation Testing Parameters   [ Time Frame: Study day five. ]
  Show Outcome Measure 10


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
  1. lower than expected incidence of VTE events
  2. Control group patients were followed for 5 days, while TEG-guided group was followed as long as in SICU
  3. adherence to VTE prophylaxis with Daltaparin was significantly low in the TEG-guided group


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Ernest E. Moore
Organization: Denver Health Medical Center
phone: 303.602.1820
e-mail: Ernest.Moore@dhha.org


No publications provided


Responsible Party: Ernest Moore, Denver Health and Hospital Authority
ClinicalTrials.gov Identifier: NCT01050153     History of Changes
Other Study ID Numbers: COMIRB # 09-0753
Study First Received: January 13, 2010
Results First Received: August 14, 2013
Last Updated: November 28, 2014
Health Authority: United States: Institutional Review Board